Kuros Announces Allowance of US Patent for the Local Application of Parathyroid Hormone (PTH) for Bone Healing
ZURICH, July 19, 2011 /PRNewswire/ –
Kuros Biosurgery AG, a biotechnology company focused on the development
of novel biomaterials and bioactive-biomaterial combination products for
trauma, wound and spinal indications, announced today that it has received
Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office. The now
allowed application acknowledges that Kuros has been first in showing that
parathyroid hormone (PTH) when applied locally in a matrix to a bone defect
has the ability to improve bone healing. Kuros has already demonstrated the
clinical utility of this proprietary approach to bone healing in two large
phase II studies in trauma patients which have reported previously.
Kuros is developing a portfolio of biomaterial, and
bioactive-biomaterial combination, products. The Company’s product
candidates are based on two different matrix technology platforms. Kuros’
most advanced products are based on a fibrin matrix and include KUR-111 and
KUR-113 which have achieved positive results in large Phase II trials for
tibial plateau fractures and tibial shaft fractures respectively.
Didier Cowling, Chief Executive Officer at Kuros says: “This patent will
give Kuros broad protection on the concept of locally applied PTH to improve
bone healing. Obtaining the notice of allowance for this US patent
application further builds on Kuros’ proprietary position in local
treatments for bone generation and healing”.
The Notice of Allowance for US 11/679,807 with its broad scope of
protection follows US 7,247,609, US 6,331,422, US 6,607,740, EP 1 465 989,
EP 1 124 590, EP 1 280 566 and patents in many other countries which protect
Kuros` approach with PTH and its incorporation into matrices for local
Kuros is a biotechnology company that is focused on the development of
novel biomaterials and bioactive-biomaterial combination products for
trauma, wound and spinal indications.
Kuros has two biomaterial technology platforms, one based on fibrin
sealants and the other based on its own proprietary synthetic technology
that can mimic fibrin in many of its attributes. These materials can be used
alone or in combination with biologically active molecules.
Kuros’ combination products are designed to mimic the body’s natural
healing process. The products consist of fusion proteins of naturally
occurring bioactive factors, covalently incorporated into fibrin or
synthetic matrices. The incorporation of the biologically active molecules
into the injectable matrices aims to maximize their activity by retention at
the site of action. Kuros products are designed to combine ease of
application with localized delivery. Kuros has a number of methodologies to
achieve the desired retention and release profiles of the biologically
Kuros’ has a diverse pipeline of product candidates with its most
advanced product candidates being in trauma and wound care.
Since its creation, Kuros has raised over $150 million. The company is
located in Zurich, Switzerland.
Press Enquiries Kuros Didier Cowling, CEO +41(0)44-200-56-62 Alistair Irvine, Director of Business Development +41(0)44-200-56-62 For Swiss Media Enquires: IRF Communications Martin Meier-Pfister +41(0)43-244-81-40 Jan Gregor +41(0)43-244-81-54 For International Media Enquires: Citigate Dewe Rogerson David Dible, Nina Enegren +44(0)207-638-9571
SOURCE Kuros Biosurgery AG